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CFS by RT modality (p = 0.62, p = 0.87, p = 0.76) or CT regimen 
(p = 0.94, p = 0.78, p = 0.90). 
Conclusions: IMRT and HT differ with respect to dose 
homogeneity and normal-tissue sparing. Acute toxicity was 
significantly increased in patients receiving MMC2 compared to 
MMC1. However, there were no differences in outcome based on 
either RT modality or chemotherapeutic regimen between these 
cohorts. 
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Purpose: Image-guided, intensity-modulated radiation therapy 
(IG-IMRT) allows accurate, conformal treatment of the prostate 
bed post-prostatectomy. However, a large planning target 
volume (PTV) is still required to address deformations due to 
variations in rectum and bladder filling. Adaptive radiation 
therapy is a potential solution that has not been explored in this 
setting. We present the results of a feasibility study of ART for 
post-prostatectomy prostate cancer. 
Material and Methods: Twenty-one patients were initially 
planned and treated with IG-IMRT according to our institutional 
standard. The original clinical target volume, plus the CTV that 
was recontoured on cone-beam CT (CBCT) images from the first 
four fractions and used to create an adapted PTV. A new plan 
using the adapted PTV was implemented on fraction 7 and used 
for the remaining 27 fractions. The primary study endpoint was 
improvement in dosimetric plan quality. 
Results: All patients were successfully recontoured and 
replanned within the allotted 3 day period, requiring a mean of 
1.9 days (0.4 days standard deviation). The mean adapted PTV 
volume was 19% (60 cc) smaller than the standard PTV (p < 
0.001), and smaller than standard PTV for 20 of 21 patients. 
Reconstruction of the dose delivered on 102 recontoured weekly 
CBCT following adaptation shows the mean CTV coverage is 
similar although slightly lower in ART plans (mean CTV D99 94% 
[1%]) compared to if the unadapted standard plans had been 
continued (96% [1%]) (p < 0.001). Reconstructed small bowel dose 
demonstrated fewer fractions of the ART plan with small bowel 
exceeding 75% of the prescription dose (11% ART fractions versus 
18% standard, p < 0.01). 
Conclusions: ART for post-prostatectomy prostate cancer is 
feasible and safe, facilitates PTV volume reduction while 
maintaining reasonable CTV coverage, and can reduce the dose 
to adjacent normal tissues. 
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Purpose: Metastatic renal cell carcinoma (mRCC) represents one 
of the few end-stage malignancies where aggressive treatment 
to the primary tumour (i.e. cytoreductive nephrectomy) is 
associated with a survival benefit. Criteria published by (Heng et 
al. 2009) have assisted in the risk-stratification of patients who 
may benefit most from this, but many are not surgical candidates 
due to medical inoperability or unresectable disease. We 
hypothesized that SABR could serve as a safe alternative 
modality for such patients. Our study objectives were to report 
on technical considerations, toxicity, and outcomes of our 
institutional experience with SABR for large renal tumours. 
Methods and Materials: In this research ethics board approved 
study, a retrospective review of patient databases was 
conducted to identify patients with RCC (presumed or biopsy-
confirmed) who underwent SABR at our institution between 
January 2008 and June 2015. Clinical and dosimetric data were 
abstracted from electronic and paper records. Toxicity was 
quantified using the CTCAE v4.0 and the RECIST classification 
was used to evaluate radiographic response. Median overall 
survival and follow up were calculated using the Kaplan-Meier 
and reverse Kaplan-Meier methods, respectively. 
Results: We identified 11 patients of median age 79 (range 61-
87), the majority (n = 9) with Stage III-IV disease. Patients were 
classified as poor (n = 5) or intermediate (n = 4) risk based on the 
model by Heng et al. SABR was directed to the tumour alone (n 
= 7) or the whole kidney (n = 4). Median tumour size, GTV, and 
PTV were 9.5 cm (range: 7.5-24.4), 482.6 cm3 (range: 185.7 – 
4617.8), and 819.3 cm3 (range: 313.4 – 5704.3), respectively. 
SABR was delivered in five fractions to a dose of 25 (n = 6), 30 (n 
= 3), 35 (n = 1), or 40 Gy (n = 1). Favourable coverage of 
treatment volumes and largely acceptable doses to organs at risk 
were achieved via IMRT (n = 6), Helical Tomotherapy (n = 3), or 
VMAT (n = 2). Median follow up was 12.9 months (95% confidence 
interval [CI]: 1.3 – 56.1). Five cases of CTCAE Grade 1 toxicities 
were reported. Grade 2 diarrhea and probable Grade 3 nausea 
were observed in one patient with the largest tumour treated in 
the study. In patients with follow up imaging (n = 7), SABR 
resulted in stable disease (n = 5), partial response (n = 1), or 
progressive disease (n = 1). Median overall survival was 20.4 
months (95% CI: 4.24 – N/A) 
Conclusions: SABR can be delivered safely and with minimal 
toxicity, as demonstrated in this small retrospective cohort of 
patients with large primary renal tumours. A Phase I study at our 
institution is currently underway to prospectively determine 
maximum tolerable and optimal dosing in this setting 
(NCT02264548). 
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Purpose: Low baseline testosterone level is a known adverse 
prognostic factor in patients treated with prostatectomy and a 
positive predictive factor in patients treated for metastases or 
recurrences. Little is known about its importance in radiotherapy 
for localized prostate cancer. 
Methods and Materials: Patients treated at our institution in 
prospective Phase 2 or 3 clinical trials and who had a baseline 
total testosterone level available before initiation of any 
treatment were selected from our institutional database. All 
patients received between 70-79.2 Gy in 1.8-2 Gy per fraction or 
a biological equivalent dose in hypofractionated protocols. A 
total testosterone (TT) level of < 10.4 nmol/L (< 300 ng/dL) was 
chosen as a cut-off, this being often used to define low TT levels. 
Results: A total of 360 patients were identified. Of these, 71% 
had D’Amico low- or intermediate-risk cancers, the remainder 
having high-risk cancers. Fifty-eight percent were > 70 years old 
and 29% had a BMI > 30 kg/m2 (BMI data was available in 76% of 
the patients). Median follow up was 67 months (IQR 40-90 
months). Baseline TT level was < 10.4 nmol/L in 58% of patients. 
Sixty-four patients (18%) experienced biochemical recurrence 
(BCR). Median time to BCR was 57 months (range 5-112 months). 
Fifty-five patients died at a median of 64 months after treatment 
(IQR 36-80 months). Testosterone as a continuous variable was 
not correlated to age (p = 0.27) and only weakly inversely 
correlated to BMI (r=-0.16, p = 0.009). On univariate analysis, 
patients with a TT< 10.4 nmol/L value had significantly lower 
rate of BCR (p = 0.044). This effect was maintained on 
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multivariate analysis adjusted for disease aggressiveness, age 
and BMI. A TT> 10.4 nmol/l was associated with a hazard ratio of 
1.78 (95% CI 1.06-2.98, p = 0.03) for BCR. This difference in BCR 
appeared as a split on the Kaplan-Meier curve only five years 
after treatment. TT did not have an influence on overall survival 
(p = 0.28). 
Conclusions: Low baseline TT level is an independent prognostic 
factor associated with a lower BCR rate. This effect appears only 
five years after radiotherapy treatment. The results are to the 
contrary to what has been shown from patients treated with 
radical prostatectomy. 
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Purpose: Current clinical practice guidelines support the 
engagement of prostate cancer patients in their cancer care. 
However, the optimal timing of, and the most preferred sources 
of information provision and decision support desired by prostate 
cancer patients has not been systematically explored. In order 
to inform the design of strategies for information provision and 
decision support, we sought to determine prostate cancer 
patients’ preferences by conducting a systematic survey of 
recently diagnosed patients. 
Methods and Materials: Surveys were conducted in British 
Columbia, Alberta and Saskatchewan. Based on power 
calculations and estimated response rates, a random sample of 
prostate cancer patients in each provincial registry diagnosed in 
late 2012 was invited to participate. 
Results: Provincial response rates were 46%-55%, total n = 1007. 
Across provinces, mean age was 69 years. During the interval 
between diagnosis and the treatment decision, preferred 
information sources (not mutually exclusive) were the urologist 
(90%), family physician (85%), and radiation oncologists (58%). 
The Radiation Oncologist being identified as information source 
was highly dependent on whether the patient was managed with 
prostatectomy only (39%) versus primary radiotherapy (92%, p < 
0.01) whereas both groups identified the urologist as an 
important source (98% versus 94% respectively). Across all 
patients, 73% wanted printed information and 58% wanted 
information from the internet. Barriers to obtaining information 
from physicians included patients’ perception of physicians not 
having enough time (27%), worrying about physician time (21%), 
and worrying about asking too many questions (15%). Barriers to 
obtaining information from books and from the internet, 
respectively, included uncertain quality (37% and 46%, 
respectively), unclear if personally applicable (39% and 41%), and 
poor search skills (31% and 20%). Recommended facilitators for 
providing information included a person to guide its acquisition 
(71%), providing printed information (69%), and someone to 
answer questions: in person (77%), over the phone (53%), or via 
email (43%). Even if access was easy, 27% would not want 
information from the internet, and 13% would not want any 
printed information. Regarding decision making, 18% would have 
liked more help with their decision, though half of that group 
(53%) indicated that they felt well informed. 77% of all 
respondents either used decision support or would have wanted 
to if they had known about it. Recommended timing for decision 
support included before meeting any specialists (11%), at the 
urologist visit (31%), and after all specialist visits before the 
decision is made with a doctor (35%). 
Conclusions: Most prostate cancer patients want information 
and decision support but vary in where, when, and preferred 
medium. Optimal support needs to be multi-faceted and flexible. 
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Purpose: We previously identified circulating miRNA in 
metastatic prostate cancer patients that are associated with 
early castrate resistance (< 2 years). The current study 
determined whether the predictive miRNA were associated with 
time to castrate resistance (CRPC) in PSA recurrent and high-risk 
adjuvant patients. 
Methods and Materials: Patients from a prospective biomarker 
trial were categorized into three groups: 1) CRPC within two 
years of ADT, 2) CRPC greater than two years, and 3) patients 
remaining ADT sensitive. Total RNA was isolated from pre-
treatment plasma using the miRNeasy kit (Qiagen). For quality 
control, known concentrations of cel-miR-39 were added prior to 
RNA isolation. Isolated miRNA was subjected to reverse 
transcription (RT) using the miScript II RT Kit and primers specific 
to miRNA of interest. Quantification of individual miRNAs was 
performed by qPCR using the miScript SYBR Green PCR Kit and 
specific primers for miRNAs of interest following RT. 
Quantification of relative levels of miRNAs between samples was 
determined following comparison of the CT method of relative 
quantification following normalization to cel-miR-39 and the 
endogenous control SNORD61. 
Results: Previous work in metastatic patients identified 3 miRNA 
associated with development of early versus delayed CRPC. In 
the current study similar trends were observed for the third 
miRNA which was increased in early CRPC compared to other two 
groups. The second miRNA showed more variable expression 
amongst the three cohorts, and was generally lower in those 
patients who developed early CRPC. First miRNA was also lower 
in patients with early CRPC as compared other two groups, 
similar to our original findings in metastatic patients. 
Conclusions: A previously identified miRNA signature of early 
castrate resistance in metastatic patients appears to be 
applicable to PSA recurrent and high-risk patients. Future work 
will validate these findings in additional patients from our trial 
and independent cohorts. 
141  
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Objectives: To assess the psychometric properties of a French 
Canadian version of the Expanded Prostate Cancer Index 
Composite Instrument (EPIC-50), among a clinical sample of 
prostate cancer patients. 
Methods and Materials: The validity of the French Canadian 
version of the EPIC-50 was assessed among patients from the 
radiation oncology and urology departments of CHU de Québec. 
A total of 251 patients were recruited. Participants taking part 
in the sensitivity to change study (n = 51) were asked to complete 
a battery of self-report scales at their consultation and at a 
follow up visit at the hospital, approximately six months after 
the initiation of their treatment. Another subsample of 68 
patients completed the EPIC on two occasions separated by two 
weeks to estimate temporal stability. The battery comprised the 
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